Online Education
- Home
- Online Education
Important Note
You will need to login first in order to enroll or view an activity. Login Here
*Note: ✔ = Contact Hours Provided AND ✖ = No Contact Hours Provided
How Does Blood Clot? Details
Title
How Does Blood Clot?
Purpose Statement
The purpose of this activity is to enable the learner to improve understanding of and increase interest in the basic concepts involved in the complex coagulation process to ultimately improve patient care.
Educational Objectives
- Examine the coagulation process from the point of injury to clot resolution.
- Evaluate the platelet reaction step of normal hemostasis.
- Differentiate among the three coagulation pathways, including the various clotting factors that participate in hemostasis.
Target Audience
Nurses and other healthcare staff employed within or affiliated with the U.S. Hemophilia Treatment Center (HTC) network.
Topics/Content
An animated module illustrating the coagulation cascade.
Faculty w/ credentials
- Roshni Kulkarni, MD
- Usha M. Reddy, MD
- Bruce L. Evatt, MD
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813, toll-free 877-256-8837, or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High speed internet connection
- Any one Internet browser:
- Firefox (Most Current Version)
- Safari (Most Current Version)
- Google Chrome (Most Current Version)
- MS Internet Explorer (Most Current Version)
- Cookies and JavaScript must be enabled in all browsers.
- All browsers must have flash plug in installed and enabled.
- Cookies and JavaScript must be enabled in all browsers.
- All browsers must have flash plug in installed and enabled.
- Please note: This program requires FLASH PLAYER. If your computer does not have FLASH PLAYER, or does not allow such files to play, you will not be able to view this program. You will need to speak to your institutions Information Technology department about enabling or installing FLASH PLAYER onto your computer.
Understanding Hemophilia Details
Activity Number and Title
24HT00086 Understanding Hemophilia
Release Date
July 15, 2024
Expiration Date
5:00 PM Eastern, July 15, 2026
The estimated time to complete this activity is 120 minutes.
Purpose Statement
"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.
Activity Description
This 6-part online learning activity introduces basic concepts of hemophilia.
Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.
Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.
Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.
Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.
Part 5: Non-Factor Therapies covers gene therapy for hemophilia and the novel agent emicizumab. Gene therapy includes goals of therapy, delivery of gene therapy, eligibility criteria, patient readiness considerations pre- and post-therapy, and long-term follow-up post-therapy.
Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.
Target Audience
This accredited continuing education activity is designed for physical therapists, nurses, nurse practitioners, social workers and other clinical and non-clinical staff at federally recognized U.S. Hemophilia Treatment Centers who wish to develop an understanding of basic concepts of hemophilia. This activity is particularly appropriate for clinicians within their first six months of employment at an HTC.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
- Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
- Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
- Describe the goals of hemophilia gene therapy and describe the mechanism of action for hemophilia gene therapy
- Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
- Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases
Faculty
- Jennifer Maahs, MSN, PNP
- Amy Shapiro, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity.
- Complete the evaluation.
- Complete the post-test with a score of 80% or better.
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accredited Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
SOCIAL WORKERS
As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 2 clinical continuing education credits. The content level of this activity is beginner.
PHYSICAL THERAPISTS
This activity is approved for physical therapy continuing education units (CEUs) through the California Physical Therapy Association (CPTA) (Approved for 0.2 CEUs by CPTA #24-215) from May 24, 2024 to May 24, 2025. While many states recognize continuing education credits from CPTA, please verify with your state Board that these credits are acceptable in your state. To learn more about CPTA, visit https://www.ccapta.org.
Financial Support
Partners in Bleeding Disorders Education Programs are currently supported by educational grants from Genentech, a member of the Roche Group; Takeda Pharmaceuticals U.S.A., Inc.; and Novo Nordisk.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Edge
- Cookies and JavaScript must be enabled in the browser
Multidisciplinary Bleeding Disorders Comprehensive Care Team: Roles and Responsibilities
- Credits: 0.75 (ANCC)
- Expiration Date: April 17, 2026
Multidisciplinary Bleeding Disorders Comprehensive Care Team: Roles and Responsibilities Details
Activity Number and Title
24HT00085 - Multidisciplinary Bleeding Disorders Comprehensive Care Team: Roles and Responsibilities
Release Date
April 18, 2024
Expiration Date
5:00 PM Eastern, April 17, 2026
The estimated time to complete this enduring material is 45 minutes.
Purpose Statement
At U.S. Hemophilia Treatment Centers, care is delivered by a multidisciplinary team of health care specialists with expertise in prevention and management of complications of bleeding disorders. Best practice guidelines exist on the ideal composition of this team and expected contributions of each team member. This PartnersPRN online learning activity aims to enable the learner to develop competencies regarding the roles and responsibilities of members of the multidisciplinary bleeding disorders comprehensive care team.
Activity Description
This online learning activity includes content about the roles and responsibilities of members of the core and extended multidisciplinary bleeding disorders comprehensive care teams at federally recognized Hemophilia Treatment Centers (HTCs). These roles and responsibilities are derived from best practice guidelines issued by the Medical and Scientific Advisory Council (MASAC) of the National Bleeding Disorders Foundation (NBDF). Based on these guidelines, the activity identifies core team members as the hematologist, nurse, physical therapist, social worker, as well as a program coordinator, administrative staff, and round-the-clock access to laboratory specialists in a specialized coagulation laboratory. Extended team members include any number of specialists either on HTC staff or by referral to community providers, including dental/oral health professionals, genetic counselors, pharmacists, insurance specialists/financial managers, hepatologists/infection disease specialists, registered dietitians/nutritionists, orthopedists, obstetricians/gynecologists, data managers, and clinical research coordinators.
Target Audience
This accredited continuing education activity is designed for nurses, nurse practitioners, physical therapists, social workers, and other clinical and non-clinical staff at federally recognized U.S. Hemophilia Treatment Centers who require knowledge about the roles and responsibilities of members of the multidisciplinary comprehensive care team.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Identify best practice guidelines regarding multidisciplinary management of bleeding disorders
- List members of the core and extended multidisciplinary bleeding disorders comprehensive care teams as identified in best practice guidelines
- Describe the roles and responsibilities of members of the core and extended multidisciplinary bleeding disorders comprehensive care teams
Faculty
- Susan Cutter, MSW, LCSW, MPA
- Karen Droze, MS
- Nicole Hroma, PT
- Pamela R. Jarrell, BSN, RN, RN-BC
Requirements for Successful Completion
In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test, your certificate of completion will be available to print or save
Accredited Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, at 463-238-1186 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Edge
- Cookies and JavaScript must be enabled in the browser
The 340B Pharmacy Program and the HTC
- Credits: 0.5 (ANCC)
- Expiration Date: January 9, 2026
The 340B Pharmacy Program and the HTC Details
Special Note
Before completing this module, you may want to complete the PartnersPRN online learning activity titled U.S. Hemophilia Treatment Center Network: The Big Picture or if its no longer available on the site, contact Partners partners@ihtc.org for a copy of the PDF slides.
Activity Number and Title
24HT00069 The 340B Pharmacy Program and the HTC
Release Date
January 10, 2024
Expiration Date
5:00 PM Eastern, January 9, 2026
The estimated time to complete this enduring material is 30 minutes.
Purpose Statement
The purpose of this module is to examine the 340B Pharmacy Program, its role in homecare of hemophilia, eligibility and enrollment, restrictions and requirements, and special considerations for operation of such a program.
As designated in The Veterans Health Care Act of 1992 designated federally-recognized and federally-funded Hemophilia Diagnostic and Treatment Centers (HTCs) as covered entities eligible to participate in the 340B Drug Pricing Program. HTCs were henceforth able to utilize the 340B Program to stretch federal grant funding and develop capacity to provide robust, comprehensive services to all patients served. In 2015 federal grants divided among 140+ HTCs in the U.S. totaled only $4.9 million from Health Resources and Services Administration (HRSA) (to be used for services not covered by insurance) and an additional $5 million from the Centers for Disease Control and Prevention (CDC) (earmarked for surveillance and research).1 Thus, in this era of fiscal constraint brought on by budget cuts and the effects of federal sequestration, HTC participation in the 340B Pharmacy Program has provided a critical means of financial support for HTC services enabling provision of comprehensive care for all patients seen at HTCs with these programs. Approximately 100 of the 140 HTCs participate in the 340B Pharmacy Program.2 As a condition of participation, these centers must invest all revenues from the program back into patient services, care coordination, research and other programs that directly benefit patients.
Activity Description
This module will provide a brief history of?the 340B Pharmacy Program established in 1992 under the Veterans Healthcare Act and the role of these programs in lowering costs of care and providing revenue for the HTC which must be reinvested into programs and services provided directly to HTC patients. For those HTCs in consideration of starting a 340B Pharmacy Program, this module also introduces the Office of Pharmacy Affairs requirements and regulations for such a program, including definitions of key terms and information about the application process, program maintenance, and potential program audits. Finally, this module will recommend the Hemophilia Alliance as a resource for HTCs with 340B Pharmacy Programs as well as those who are interested in learning more about the operation and management of such programs at HTCs.?
Target Audience
This accredited continuing education activity is designed for nurses, pharmacists, pharmacy technicians, and other healthcare professionals in the U.S. Hemophilia Treatment Center (HTC) Network who wish to learn more about establishing and/or managing a 340B Pharmacy Program and the role of these programs in the U.S. HTC Network.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Explain homecare provision and the role of the 340B Pharmacy Program
- Summarize the importance of Section 340B of the Veterans Health Care Act
- Describe 340B Pharmacy Program eligibility and enrollment
- Identify restrictions and requirements to operate a 340B Pharmacy Program
- Discuss special considerations of operating a 340B Pharmacy Program at a federally-recognized U.S. Hemophilia Treatment Center (HTC).
Faculty
- Jeff Blake, MBA, CEBS
- Madhu Koneru, PharmD
Requirements for Successful Completion
In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
In order for pharmacists/pharmacy technicians to claim credit for their participation in the activity, completion of the activity evaluation survey with inclusion of birth date (mm/dd) and NABP e-Profile ID # is required. UNMC will ensure that the data is provided to CPE Monitor.
Accredited Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHARMACISTS (PharmDs/RPhs) AND PHARMACY TECHNICIANS
The University of Nebraska Medical Center designates this activity for 0.5 ACPE contact hours. Pharmacists/Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity.?UAN # JA0000319-9999-24-004-H03-P / UAN # JA0000319-9999-24-004-H03-T
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 463-238-1186 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Edge
- Cookies and JavaScript must be enabled in the browser
The Partners in Bleeding Disorders Education Program is supported by an independent medical education grant(s). Travel and lodging for program participants are made possible by an at-will contribution from the Indiana Hemophilia & Thrombosis Center.
Copyright © 2024 Indiana Hemophilia & Thrombosis Center. All rights reserved. Privacy Policy | Travel Policy | Terms of Service Credits